Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Steven P. Coen Sells 1,084 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven P. Coen sold 1,084 shares of Ginkgo Bioworks stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $9.84, for a total value of $10,666.56. Following the completion of the sale, the insider directly owned 10,679 shares in the company, valued at $105,081.36. This represents a 9.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ginkgo Bioworks Price Performance

Shares of DNA stock traded up $0.78 during trading hours on Thursday, reaching $14.92. 3,094,191 shares of the company's stock were exchanged, compared to its average volume of 1,909,207. The company's 50 day moving average is $9.38 and its two-hundred day moving average is $9.22. The company has a market cap of $872.97 million, a P/E ratio of -1.63 and a beta of 1.48. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $16.85.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The business had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. As a group, analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Ginkgo Bioworks

A number of large investors have recently made changes to their positions in DNA. Bank of America Corp DE increased its position in shares of Ginkgo Bioworks by 780.6% in the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after buying an additional 3,336,964 shares in the last quarter. Erste Asset Management GmbH increased its holdings in Ginkgo Bioworks by 123.2% during the 1st quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company's stock valued at $9,405,000 after acquiring an additional 910,668 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock valued at $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Forbes J M & Co. LLP lifted its holdings in shares of Ginkgo Bioworks by 56.0% in the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after purchasing an additional 392,832 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in shares of Ginkgo Bioworks by 188.9% in the first quarter. Cubist Systematic Strategies LLC now owns 439,259 shares of the company's stock valued at $2,504,000 after purchasing an additional 287,221 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.